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DOI 10.1186/s12950-015-0064-5RESEARCH Open AccessNeutrophil-to-lymphocyte ratio, calprotectin
and YKL-40 in patients with chronic obstructive
pulmonary disease: correlations and 5-year
mortality – a cohort study
Allan Klitgaard Sørensen1*, Dennis Back Holmgaard2, Lone Hagens Mygind3, Julia Johansen4 and Court Pedersen1Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and progressive
decline in pulmonary function. Neutrophil-to-lymphocyte ratio (NLR), YKL-40 and calprotectin are biomarkers of
inflammation and predict mortality in patients with different inflammatory diseases. We aimed to investigate the
correlation between levels of these three biomarkers and neutrophil granulocyte and lymphocyte count in patients
with moderate to very severe COPD stratified by use of systemic glucocorticoids. Furthermore, we studied the ability of
these biomarkers to predict all-cause mortality.
Methods: 386 patients with moderate to very severe COPD were followed prospectively for 10 years. Patients were
divided into two groups according to systemic glucocorticoid use at baseline. Correlations between biomarkers were
assessed by Spearman’s Rho, and mortality was evaluated in uni- and multivariate Cox regression analyses with hazard
ratios (HR) and 95% confidence intervals (CI).
Results: Plasma calprotectin was positively correlated with neutrophil granulocyte count and NLR. No significant
association was found between plasma YKL-40 and the cellular biomarkers, irrespective of glucocorticoid treatment.
In the group not treated with systemic glucocorticoids, plasma calprotectin [HR 1.002 (95% CI 1.000 – 1.004)], NLR
[HR 1.090 (1.036 – 1.148)] and lymphocyte count [HR 0.667 (0.522 – 0.851)] were significantly associated with higher
mortality. In the group treated with systemic glucocorticoids, higher plasma YKL-40 was significantly associated with
mortality in univariate Cox regression analysis [HR 1.006 (1.003 – 1.008)].
Conclusions: Calprotectin was related to neutrophil granulocyte count and NLR in patients with moderate to very
severe COPD in stable phase and not in treatment with systemic glucocorticoids. Lymphopenia, higher plasma
calprotectin and higher NLR were independent predictors of increased all-cause mortality in this group. Our data
also suggests that treatment with systemic glucocorticoids has a significant impact on the ability of inflammatory
biomarkers to predict all-cause mortality.
Trial registration: ClinicalTrials.gov NCT00132860.
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Chronic obstructive pulmonary disease (COPD) is a dis-
ease characterized by progressive destruction of lung tis-
sue resulting in a decline in pulmonary function [1]. The
pathogenesis of COPD is complex. It is generally accepted
that the inflammatory response associated with prolonged
exposure to noxious gases like tobacco smoke plays an im-
portant role. The pulmonary inflammatory response is ac-
companied by a chronic low grade systemic inflammatory
response [2]. The course of disease progression in patients
with COPD is very heterogeneous [3], and this could be
due to differences in the level of inflammation. One widely
used method of prognosis assessment is the BODE index,
which compiles a panel of known predictors of mortality
among COPD patients, i.e. low body mass index (BMI),
low forced expiratory volume in 1 second (FEV1), level of
dyspnea and exercise capacity, into an index which is asso-
ciated with increased risk of mortality [4]. None of these
variables directly reflect the degree of inflammation. In-
flammatory biomarkers may help to identify a subgroup of
COPD patients with a higher level of basal inflammation
and with a more rapid disease progression [5]. In a study
by Celli et al., it was found that the ability of clinical vari-
ables – BODE, age and hospitalization history – to predict
overall mortality was improved by the addition of a panel
of selected biomarkers [6]. Only plasma IL-6 single-
handedly improved the ability to predict mortality.
The systemic inflammation is reflected by an in-
creased number of neutrophil granulocytes in the cir-
culation [2], and neutrophil granulocyte count is
associated with progression of COPD [7]. Recently,
neutrophil-to-lymphocyte ratio (NLR) has attracted at-
tention as an inflammatory biomarker. It has been
shown to be a prognostic biomarker in various inflam-
matory diseases, e.g. cardiovascular diseases [8,9], cancers
[10,11] and psoriasis [12], and NLR is elevated in patients
with COPD [13].
Calprotectin is mainly found in neutrophil granulo-
cytes, where it comprises up to 45% of the cytosolic vol-
ume, and is thought to be secreted upon cell death or by
a non-classical pathway [14-16]. It is a calcium binding
heterodimer of S100A8/S100A9 which is believed to
have both anti-inflammatory and antibacterial properties
[17]. Calprotectin is elevated in a variety of inflammatory
diseases [18-20], including respiratory diseases, and cor-
related with disease activity [21,22]. In patients suffering
from cystic fibrosis, serum levels of calprotectin de-
creased in patients treated with antibiotics, and calpro-
tectin levels measured at baseline and after treatment
were inversely correlated with FEV1 and predicted time
to next exacerbation [19]. Recently, we have shown that
plasma calprotectin predicts all-cause mortality in pa-
tients with moderate to very severe COPD in stable
phase [23].Plasma concentration of YKL-40 (also named CHI3L1)
is another potential biomarker of inflammatory activity in
patients with COPD. Plasma YKL-40 is elevated, compared
to normal levels, in patients with diseases hallmarked by
chronic low-grade inflammation; cardiovascular diseases
[24-26], cancer [27], liver fibrosis, inflammatory bowel dis-
ease and rheumatoid arthritis [28]. YKL-40 is secreted by
activated macrophages and neutrophils and by cancer cells
[29,30], and plays a role in inflammatory pulmonary dis-
ease. This glycoprotein is involved in cell proliferation and
differentiation [31], inflammation [32], angiogenesis [33]
and protects against apoptosis [34]. YKL-40 causes bron-
chial smooth cell proliferation and induces IL-8 expression
from macrophages [35], as well as other mediators of in-
flammation [36]. IL-8 is an activator of neutrophil granulo-
cytes. YKL-40 regulates cellular and tissue responses via
IL-13 receptor α2 [37]. Plasma YKL-40 is linked to disease
activity in patients with asthma, COPD and idiopathic pul-
monary fibrosis, and high YKL-40 levels are found in bron-
choalveolar lavage fluid from patients with pulmonary
diseases [38-40]. We have recently demonstrated that
plasma YKL-40 predict all-cause mortality in patients with
moderate to very severe COPD in stable phase [41].
The aim of the present study was to investigate the
correlation between plasma calprotectin and plasma
YKL-40 and levels of neutrophil granulocytes, lympho-
cytes, and NLR in patients with moderate to very severe
COPD in stable phase stratified by use of systemic glu-
cocorticoids. We also studied the ability of these bio-
markers to predict all-cause mortality in these two patient
populations.
Methods
Study participants
575 patients diagnosed with COPD, and in a stable
period of their disease, were in the period of 2001–2004
enrolled in a randomized controlled trial, which exam-
ined the effect of azithromycin 500 mg 3 days/month
during a period of 36 months. Patients’ date of death
was recorded in the Danish Central Registry and the last
follow-up was January 31st 2011. After 10 years, only
0.9% of the patients had been lost to follow up.
Primary outcome measure was post broncho dilatator
FEV1, and secondary outcome measures included quality
of life, mortality, number of hospital admissions and days
admitted in a hospital. The trial was registered at https://
clinicaltrials.gov/ct2/show/NCT00132860?term=NC
T00132860&rank=1. Ethical permission for the study
was obtained from the Regional Scientific Ethical Commit-
tee for Southern Denmark (approval number 19990031).
Primary outcome in the present study was all-cause
mortality. Inclusion criteria and exclusion criteria of the
original study are shown in Table 1. Of the 575 patients
enrolled, serum was available from 441 patients for
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ment with systemic glucocorticoids within 14 days prior
to inclusion in the study was identified retrospectively
using patient files. We excluded 55 patients due to lack-
ing or inadequate information about glucocorticoid
treatment. The present study population was 386 pa-
tients; 302 patients were classified as not using systemic
glucocorticoids within 14 days prior to inclusion, and 84
were classified as using glucocorticoids.
Plasma samples
Blood sampling was done at baseline at a time where pa-
tients were in a stable period of their disease. Samples
were taken before the first dose of study medication was
taken. Blood for EDTA plasma was centrifuged within
1 hour after sampling, and plasma samples were frozen
and stored at −80°C until analysis. Plasma concentration
of calprotectin was determined in duplicates using a
commercially available ELISA kit (Hycult Biotech, Uden,
NL). The measurement was done at the M 7641 depart-
ment, Rigshospitalet, Copenhagen, Denmark.
Plasma concentration of YKL-40 was determined in du-
plicate by a commercially available ELISA kit (Quidel,
Santa Clara, CA, USA). Plasma concentration of YKL-40
is stable for up to 16 years when frozen at −80°C degrees
[42]. The plasma samples had one cycle of freeze-thaw be-
fore analysis. The reference interval for plasma YKL-40
was determined from a previous study of 3130 healthy
subjects (1837 women, 1293 men, aged 21–84 years) from
the Danish general population [42]. They had no known
disease at the time of blood sampling in 1991–1994 and
remained healthy and alive during the 16-year follow-up
period. From this study, an age dependent correlation wasTable 1 Inclusion- and exclusion criteria of the original study
Inclusion criteria Excl
• Patients above 50 years with minimum 1 hospital admission
caused by COPD with or without exacerbation within
the last 2 years.
• End
bed
• Current smoker or ex-smoker. • Pat
• Post broncho dilatator FEV1 < 60% in stable condition
(4 weeks after hospitalization).
• Pat
• Pat
• < 300 mL broncho dilatator reversibility in FEV1. • Pat
wit
• Pat
(e.g
• Pat
• Pat
• Pre
• Ma
• Pat
tofound between age and plasma concentrations of YKL-40
and a formula has been extrapolated from this study,
which we applied to our present study.
Statistics
No glucocorticoid use: In this group of 302 patients,
NLR was available from 280 patients, lymphocyte count
from 282 patients, and neutrophil granulocyte count
from 288 patients.
Glucocorticoid use: In this group of 84 patients, NLR
was available from 70 patients, lymphocyte count from
71 patients, and neutrophil granulocyte count from 72
patients.
Analysis: The distribution of each biomarker was
inspected visually by histograms. All biomarkers
showed a violation of the normal distribution, and
Spearman’s rank correlation coefficient was used to de-
termine potential associations between plasma calpro-
tectin and plasma YKL-40 and neutrophil granulocyte
count, lymphocyte count and NLR.
Kaplan-Meier plots and univariate log-rank tests were
computed for each biomarker. Each biomarker was
dichotomized. The median of the non-glucocorticoid
group was used to divide plasma calprotectin (135.53 ng/mL)
and NLR (2.83). Lymphocyte count was divided by
the lower limit of our reference value (1.3 × 109/L).
Neutrophil count was divided by the upper limit of
our reference value (7.0 × 109/L). Plasma YKL-40 was
divided at the 75th age corrected percentile of the reference
interval [42].
We performed a univariate Cox regression analysis to
calculate hazard ratios (HR) and 95% confidence inter-
vals (CI) for each biomarker as a continuous variable.usion criteria
stage COPD with < 3 years expected survival (typically
ridden patients being dyspnoeic at rest).
ients with other known respiratory infection.
ients with known pulmonary malignancy.
ients with other pulmonary diseases than COPD.
ients with immunodeficiency. However, patients treated
h steroids can be included.
ients with known hereditary disposition to lung infections
. alpha-1-antitrypsindeficiency, cystic fibrosis or primary ciliary dyskinesia).
ients receiving long-term antibiotic treatment.
ients with known allergy or intolerance to Azithromycin.
gnant or breastfeeding women.
nifest heart, liver or renal insufficiency.
ients that, for reasons not stated above, are unlikely to be able
participate in a study period of 3 years.
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for confounders. Pre-analysis, the following parameters
were defined to be included in the analysis: age (continu-
ous covariate), gender, active smoking status at baseline,
BMI (<20), Charlson Score Index (CSI >3) and GOLD-
stage (defined as GOLD-stage 2 (inactive/moderate
COPD): 79–50 FEV1% predicted; GOLD-stage 3 (severe
COPD: 30–50 FEV1% predicted); and GOLD-stage 4
(very severe COPD: <30 FEV1% predicted)) [1]. Our Cox
regression models did not include interactions. This was
necessary in order to fit similar regression models for all
biomarkers of interest, making the models comparable.
Since our study population is small, we found it import-
ant to have a simple, transparent and replicable model,
although it may increase the risk of overlooking a con-
founding interaction [43].
Proportional hazards (PH) assumption was tested using
log-log plots and testing for time varying covariates using
likelihood ratio test statistics. Due to violation of the PH
assumption for GOLD-stage after an analysis time of
5 years, it was decided to restrict the Cox regression
model to time ≤ 5 years. In this model we had 150 events
(deaths) in the group not treated with systemic steroids,Table 2 Baseline characteristics of the study population strat
No glucocorticoid
(n = 302)
Median (IQR)
Calprotectin (ng/mL) 135.53 (97.84 – 19
Neutrophil count (x 109/L) 5.88 (4.60 – 7.32)
Lymphocyte count (x 109/L) 1.92 (1.47 – 2.46)
NLR 2.83 (2.03 – 4.57)
YKL-40 (ng/mL) 77 (53 – 119)
Age (years) 71 (64 – 75)
BMI 24.22 (20.70 – 27.7
FEV1 % predicted 40.20 (30.34 – 49.5
Median (CI 95%)
Survival time (days) 1851 (1632 – 2109
n (%)
Gender (male) 148 (49)
CSI (>3) 56 (19)
Current smoker 121 (42)
Moderate COPD 86 (28)
Severe COPD 150 (50)
Very severe COPD 66 (22)
Maintenance glucocorticoid therapy -
P-values for continuous variables are calculated with Kruskal-Wallis test. P-values for di
lymphocyte ratio. BMI: Body Mass Index. FEV1% predicted: Forced expiratory volume in
(GOLD-stage 2: 79–50 FEV1% predicted), severe COPD (GOLD-stage 3: 30–50 FEV1% pre
confidence interval. IQR: Inter quartile range.and 59 events in the steroid treated group. No violation of
the PH assumption in the model restricted to time ≤
5 years was found. Using likelihood ratio test statistics we
excluded CSI > 3 as a confounder from all 5 regressions,
as it did not contribute significantly to the analysis. Thus,
we ended up with regression models for all 5 biomarkers
adjusting for age, gender, active smoking status at baseline,
BMI < 20 and GOLD-stage. Due to severe violations of the
PH assumption for most covariates in the group using sys-
temic glucocorticoids, we were unable to fit a multivariate
Cox regression model in this group. All statistical analyses
were carried out using Stata 13 (Stata Corp LP, TX, USA).
Results
Characteristics of the study population stratified by use of
systemic glucocorticoids are given in Table 2. The patients
were characterized by having fairly advanced COPD, rela-
tively high BMI and a high age. The group using systemic
glucocorticoids had higher plasma calprotectin YKL-40,
higher NLR and neutrophil granulocyte count, lower
lymphocyte count, lower FEV1%-predicted and significantly
shorter survival time compared to the group not treated
with systemic glucocorticoids.ified by systemic glucocorticoid use
use Glucocorticoid use P
(n = 84)
Median (IQR)
3.46) 176.05 (123.64 – 234.20) <0.01
8.47 (6.68 – 10.20) <0.01
1.43 (1.01 – 1.78) <0.01
5.79 (4.17 – 9.66) <0.01
105 (55 – 140) 0.059
70.5 (65 – 77.5) 0.305
0) 24.17 (20.86 – 27.69) 0.914
0) 34.84 (27.89 – 42.57) <0.01
Median (CI 95%)
) 1080 (680 – 1283) <0.01
n (%)
43 (51) 0.723
20 (24) 0.283
32 (38) 0.744
18 (21)
42 (50)
24 (29)
n (Median dose)
73 (10 mg/day)
chotomous variables are calculated with chi-squared test. NLR: Neutrophil-to-
1 second, % predicted. CSI: Charlson Score Index for comorbidity. Moderate COPD
dicted), and very severe COPD (GOLD-stage 4: <30 FEV1%predicted). CI 95%: 95%
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Figure 1 shows the correlation between plasma calprotec-
tin and the three cellular biomarkers. A significant positive
correlation was found between plasma calprotectin and
neutrophil granulocyte count, and between plasma calpro-
tectin and NLR. A negative correlation (but not statisti-
cally significant) was found between plasma calprotectin
and lymphocyte count. There was no correlation between
plasma YKL-40 and any of the cellular biomarkers
(Figure 2).
Kaplan-Meier plots are shown in Figure 3. Low lympho-
cyte count and high NLR were significantly associated
with higher mortality. No significant difference in mortal-
ity was found between the levels of plasma calprotectin,
plasma YKL-40 and neutrophil granulocyte count.Figure 1 Relationship between calprotectin and neutrophil granulocy
use. Spearman’s rank correlation coefficient (Rho) and corresponding p-val
lymphocytes = 30 × 109/L was removed from the graph in the non-glucocUnivariate regression analysis showed that plasma calpro-
tectin, NLR and lymphocyte count were predictors of
mortality, whereas plasma YKL-40 and neutrophil gran-
ulocyte count were not. When adjusting for possible con-
founders, plasma calprotectin, NLR, and lymphocyte
count were significantly associated with mortality
(Table 3).
Patients treated with glucocorticoids
84 patients were treated with systemic glucocorticoids; 73
patients were on a long term maintenance therapy (median
daily dose of 10 mg, range 5–40 mg) and 11 patients were
classified as not having ended a high dose treatment within
14 days prior to inclusion (Table 2). There was a significant
positive correlation between plasma calprotectin andte count, lymphocyte count* and NLR stratified by glucocorticoid
ues are displayed in the top right corner of each plot. *An outlier of
orticoid group for aesthetic purposes.
Figure 2 Relationship between YKL-40 and neutrophil granulocyte count, lymphocyte count* and NLR stratified by glucocorticoid use.
Spearman’s rank correlation coefficient (Rho) and corresponding p-values are displayed in the top right corner of each plot. *An outlier of
lymphocytes = 30 × 109/L was removed from the graph in the non-glucocorticoid group for aesthetic purposes.
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nificant correlations were found between plasma YKL-40
and the cellular biomarkers (Figure 2).
Kaplan-Meier plots are shown in Figure 4. High
plasma YKL-40 level was associated with shorter overall
survival. Univariate cox regression analysis showed that
plasma YKL-40 was significantly associated with mortality
(Table 3).
Discussion
We investigated potential cellular and plasma biomarkers
of inflammatory activity in two populations of patients
with moderate to severe COPD. One did not receive treat-
ment with systemic glucocorticoids and one group re-
ceived or had recently been treated with systemic
glucocorticoids. We found that plasma calprotectin waspositively correlated with neutrophil granulocyte count
and NLR. These correlations appear attenuated in the
group treated with systemic glucocorticoids. No significant
associations were found between plasma YKL-40 and the
cellular biomarkers. High plasma calprotectin, low
lymphocyte count and high NLR were independent pre-
dictors of all-cause mortality in patients not treated with
glucocorticoids. On the other hand, high plasma YKL-40
was associated with increased mortality in the glucocortic-
oid treated group.
As expected, a positive correlation was found between
plasma calprotectin and neutrophil granulocyte count.
However, this does not mean that plasma calprotectin is
just a reflection of total blood neutrophil count. Calprotec-
tin is released almost entirely from dead neutrophil granu-
locytes and neutrophil granulocytes with disrupted
Figure 3 Kaplan-Meier survival estimates for each biomarker in the group not treated with systemic glucocorticoids. Calprotectin
dichotomized at median (135.5 ng/mL). NLR dichotomized at median (2.83). Neutrophil count dichotomized at upper limit of reference value
(7 × 109/L). Lymphocyte count dichotomized at lower limit of reference value (1.3 × 109/L). YKL-40 dichotomized at 75th age corrected percentile.
NLR: Neutrophil-to-lymphocyte ratio.
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flect the number of neutrophil granulocytes currently par-
ticipating in inflammatory activity, and not just their total
number. As neutrophil granulocyte activity is related to
airway inflammation in patients with COPD [44], our
finding adds evidence to the hypothesis that plasmacalprotectin may be a biomarker of airway inflammation
in patients with COPD.
In the glucocorticoid treated group, there was a signifi-
cantly lower lymphocyte count and higher plasma calpro-
tectin and YKL-40, higher neutrophil granulocyte count
and higher NLR. This may be explained partly by an effect
Table 3 Results of uni- and multivariate Cox regressions for each biomarker restricted to time ≤ 5 years
No glucocorticoid use
Unadjusted* Adjusted**
HR (CI 95%) P HR (CI 95%) P
Calprotectin 1.002 (1.000 – 1.004) 0.031 1.002 (1.000 – 1.004) 0.016
Neutrophil count 1.039 (0.978 – 1.103) 0.213 1.035 (0.971 – 1.103) 0.296
Lymphocyte count 0.604 (0.475 – 0.768) <0.01 0.667 (0.522 – 0.851) <0.01
NLR 1.104 (1.051 – 1.159) <0.01 1.090 (1.036 – 1.148) <0.01
YKL-40 1.001 (0.999 – 1.002) 0.318 1.001 (1.000 – 1.003) 0.086
Glucocorticoid use Unadjusted*
HR (CI 95%) P
Calprotectin 1.001 (0.998 – 1.003) 0.559
Neutrophil count 1.035 (0.945 – 1.133) 0.462
Lymphocyte count 0.946 (0.580 – 1.545) 0.825
NLR 1.010 (0.966 – 1.056) 0.665
YKL-40 1.006 (1.003 – 1.008) <0.01
*Univariate Cox regression. ** Multivariate Cox regression adjusting for gender, age at baseline, GOLD-stage, smoking status at baseline and BMI < 20. NLR:
Neutrophil-to-lymphocyte ratio. HR: Hazard ratio. CI 95%: 95% confidence interval.
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the glucocorticoid group. Systemic glucocorticoids cause
lymphopenia [45] and neutrophilocytosis [46], and
consequently NLR will increase in patients treated with
glucocorticoids. The patients treated with systemic gluco-
corticoids had significantly lower mean FEV1% predicted
than the non-treated patients, suggesting that they had
more advanced or more aggressive disease, and that the
difference in biomarker levels to some degree could reflect
these differences (Table 2). Patients in the glucocorticoid
treated group may be characterized as a systemic inflam-
matory phenotype as proposed by Agusti et al. [5].
In the glucocorticoid treated group, plasma calprotec-
tin was positively correlated with neutrophil granulocyte
count and NLR, whereas plasma YKL-40 was not corre-
lated with any of the cellular biomarkers. We found no
noticeable differences in correlations between plasma
biomarkers and cellular biomarkers between the two pa-
tient groups.
The monitoring of systemic inflammatory biomarker
blood levels may potentially provide an additional level
of risk stratification in patients with COPD. Useful bio-
markers that reflect disease severity and respond to
treatment are receiving increasing attention [47]. Usage
of the conventional biomarker, C-reactive protein, in risk
management of COPD is hampered by inconsistent re-
sults and a high degree of variability [48-50].
To our knowledge, this is the first study to investigate
the usefulness of leukocyte subpopulations in the predic-
tion of mortality in patients with moderate to very se-
vere COPD. We found that low lymphocyte count was a
significant predictor of increased mortality. A growinginterest has been on lymphopenia and NLR as predictors
of mortality in various clinical settings. Low lymphocyte
count is associated with poor outcomes in patients suf-
fering from acute medical conditions such as sepsis [51],
bacteremia [52] and trauma [53], and also in patients
with chronic diseases such as cardiovascular diseases
[54], cancers [55] and inflammatory bowel disease [56].
The mechanism of lymphopenia in critically ill patients in-
volve apoptosis and redistribution of lymphocytes [57,58],
but little is known about the causes of lymphopenia in pa-
tients with chronic inflammatory diseases. Lymphopenia is
associated with age [59] and poor nutritional status [60],
which also characterizes COPD [61].These factors were
adjusted for in our regression models. Lymphopenia ap-
pears to be a biomarker of poor overall survival in general,
and not specific to COPD.
In contrast, we found no association between neutro-
phil granulocyte count and mortality. This is surprising
since neutrophil granulocyte count has previously been
described as a predictor of mortality [6]. The statistical
power of our study may not have been sufficient to de-
tect such associations. The reason for the development
of neutrophilocytosis in patients with COPD is not fully
understood, but it is hypothesized to be a result of “over-
spill” from the airway inflammation that characterizes
COPD [2].
NLR, the simple ratio obtained from a differential
blood cell count, was associated with mortality in our
study. NLR provides information beyond that of a
complete white blood cell count (high neutrophil gran-
ulocyte count reflecting systemic inflammation and lym-
phopenia reflecting immune competence).
Figure 4 Kaplan-Meier survival estimates for each biomarker in the group treated with systemic glucocorticoids. Calprotectin
dichotomized at median of non-glucocorticoid group (135.5 ng/mL). NLR dichotomized at median of non-glucocorticoid group (2.83). Neutrophil
granulocyte count dichotomized at upper limit of reference value (7 × 109/L). Lymphocyte count dichotomized at lower limit of reference value
(1.3 × 109/L). YKL-40 dichotomized at 75th age corrected percentile. NLR: Neutrophil-to-lymphocyte ratio.
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plasma YKL-40 were independent predictors of mortality
in this same cohort of patients without stratifying for sys-
temic glucocorticoid use [23,41]. In the present study,
plasma calprotectin was a significant biomarker of mortal-
ity in the patients not treated with glucocorticoids,whereas plasma YKL-40 was not. Our results suggest that
calprotectin identifies a subgroup of patients with higher
mortality.
In the patients treated with glucocorticoids, plasma cal-
protectin, neutrophil granulocyte count, lymphocyte count
and NLR were not associated with mortality, whereas
Sørensen et al. Journal of Inflammation  (2015) 12:20 Page 10 of 12higher plasma YKL-40 was a predictor of mortality. This
group included only 84 patients, and despite 59 fatalities
the statistical power may not have been strong enough to
detect associations with the other markers.
An important pharmacological effect of systemic glu-
cocorticoids is that they may cause significant neutro-
philocytosis and lymphopenia. This may explain why
neutrophil count, lymphocyte count and NLR do not act
as markers of mortality in this group of patients. The ef-
fect of glucocorticoids in patients with COPD on plasma
calprotectin and YKL-40 levels has not previously been
described. S100A8 and S100A9 expression in mice is
inhibited by glucocorticoids [62]. Since systemic gluco-
corticoids induce neutrophilocytosis and plasma calpro-
tectin level is positively correlated with neutrophil
granulocyte count, we hypothesize that though glucocor-
ticoids may inhibit expression of calprotectin in humans,
the effect of neutrophilocytocis is more profound than
this inhibition. Consequently, plasma calprotectin will
increase with systemic glucocorticoid treatment, and like
the cellular markers lose its ability to be a predictor of
mortality. This may explain why plasma calprotectin
level is not a marker of mortality in this group.
Treatment with glucocorticoids in combination with
disease modifying anti-rheumatic drugs decreases serum
YKL-40 in patients with RA [63]. This decrease is prob-
ably a reflection of decreased inflammatory activity, and
not a direct effect on YKL-40. In our study, plasma
YKL-40 was the only significant predictor of all-cause
mortality in the COPD patients treated with systemic
glucocorticoids, whereas it was non-significant in the
group not using systemic glucocorticoids. Plasma YKL-
40 may be a better predictor of mortality in patients with
more severe inflammation than in patients with low-
grade basal inflammation. Although the exact role of
YKL-40 in the pathogenesis of COPD is unknown, given
its characteristics it can be speculated that it is more
than a biomarker reflecting inflammation, but rather an
active player in the inflammatory cascade. A recent
study has demonstrated that anti-YKL-40 antibody
therapy inhibits tumor vascularization and progression
in mice with glioblastoma [64]. This places YKL-40 as
a potential therapeutic target, which may not only
be confined to cancer diseases, but also to inflammatory
diseases.
The finding of a difference in the ability of inflamma-
tory biomarkers to predict mortality between COPD pa-
tients treated with or without systemic glucocorticoids
presents new challenges. Although this difference may
not be due to systemic glucocorticoid treatment, it is an
important question to address. Regular treatment with
systemic glucocorticoids in patients with COPD is now
obsolete, but the momentary use of systemic glucocorti-
coids is a key treatment in many diseases. Therefore,studies are called for to investigate the effect of systemic
glucocorticoids on inflammatory biomarkers and their
ability to predict poor survival.
Our study has some limitations. Data regarding sys-
temic glucocorticoid treatment was collected retrospect-
ively, and the indications for their use were in most
cases unknown to us. The use of long term systemic
treatment with glucocorticoids was probably mostly used
in patients with many and severe episodes of acute ex-
acerbation, meaning that the group of patients in gluco-
corticoid treatment may be significantly different from
the group that did not receive glucocorticoids. There-
fore, direct comparison between the group should not
be made. Another limitation is that our cohort was small
when compared to other survival studies in patients with
COPD [65,66]. This was to some degree balanced out by
a high number of outcomes (150 deaths is well within
the 10 per covariate as suggested by Peduzzi et al. [67]).
Strengths of our study were the well-defined study
population, and the long follow-up time with almost
complete follow-up.
In conclusion, we have shown that plasma calprotectin
is correlated with neutrophil granulocyte count and NLR
in patients with moderate to very severe stable COPD
not treated with systemic glucocorticoids. Furthermore,
plasma calprotectin, NLR and lymphocyte count were
independent predictors of all-cause mortality in these
patients. We also showed that treatment with systemic
glucocorticoids may have an impact on the ability of bio-
markers to predict all-cause mortality. Validation studies
are needed to clarify the effect of glucocorticoid treat-
ment on these biomarkers and their ability to predict ad-
verse outcomes, and whether some of these biomarkers
will improve the current clinical prediction of mortality
in patients with COPD.
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